abemaciclib,anastrozole,letrozole
eli lilly,novartis
['monarch 3', 'abema', 'abemaciclib']
monarch 3 study of nsai +/- abemaciclib (cdk4/6 inhibitor) as 1l for post-menopausal women with hr+/her2- abc presented by at #esmo22 mos: 67.1 vs 54.5 months (hr 0.754, p=0.0301) mos (visceral disease pts): 65.1 vs 48.8 months (hr 0.708, p=0.0392) 
Scientific Communication Manager | Passionate about molecular oncology, clinical and translational research | Photo and music enthusiast | Tweets are mine